As biologics become increasingly complex, manufacturing success is no longer defined solely by achieving high titers. The challenge facing process development teams is to simultaneously improve productivity, reduce cost of goods sold (COGS), and maintain the product quality attributes required for regulatory approval and commercial supply.
For this reason, COGS reduction should not be viewed as a commercial manufacturing initiative. It is a process design challenge that begins during cell line development and continues through media optimization, feeding strategy design, and scale-up. Decisions made at these early stages determine not only manufacturing output but also the consistency of critical quality attributes (CQAs) such as glycosylation, charge variants, aggregation, and biological activity.
Cell culture media represents one of the most influential variables in biologics manufacturing because it directly shapes cellular metabolism. Nutrient composition affects how cells grow, utilize energy, synthesize recombinant proteins, and perform post-translational modifications.
This relationship is particularly important for glycoproteins, where variations in nutrient availability, trace metals, pH, or culture duration can alter glycosylation profiles. Because glycosylation can influence efficacy, pharmacokinetics, and immunogenicity, maintaining consistent product quality requires precise control of the cell culture environment.
Chemically defined media has therefore become the industry standard for modern biologics manufacturing. Beyond eliminating animal-derived components, chemically defined systems reduce raw material variability and provide tighter control over process inputs. This enables greater consistency in CQAs across development, scale-up, and GMP manufacturing while also reducing the risk of batch-to-batch variability.
In this context, media optimization is not simply about achieving higher productivity. It is about creating a cellular environment that consistently delivers the desired quality profile while supporting manufacturing efficiency.
As cell densities increase, nutrient demand rises rapidly. However, more feed does not necessarily translate to more product.
Excessive glucose supplementation can lead to lactate accumulation, while uncontrolled amino acid feeding may increase ammonia generation and increase in culture osmolality. Both conditions can negatively impact cell viability, productivity, and product quality. Changes in metabolic state are also known to influence glycosylation patterns and other CQAs.
Modern feed strategies therefore focus on metabolic control rather than nutrient abundance. By matching nutrient delivery to cellular demand, manufacturers can maintain cultures in a productive physiological state for longer periods, extending culture longevity while minimizing metabolic stress.
The result is a process that delivers higher yields and more consistent product quality, reducing both manufacturing costs and quality-related risks.
Traditional media optimization focuses on the composition of fresh media. However, spent media analysis provides a deeper understanding of how cells consume nutrients and generate metabolites throughout the culture lifecycle. By quantifying nutrient depletion, amino acid utilization, vitamin consumption, trace element requirements, and metabolite accumulation, scientists can identify nutrients that are limiting productivity as well as components that remain underutilized.
These insights support the development of targeted media and feed fortification strategies, where specific nutrients are supplemented according to actual cellular demand rather than increasing overall media or feed additions. This approach improves nutrient utilization efficiency and reduces the addition of excess raw materials that do not contribute meaningfully to cell growth or product formation.
From a COGS perspective, media and feed fortification can provide significant benefits. By eliminating unnecessary nutrient excess, manufacturers can reduce consumption of costly media components, lower feed requirements, decrease waste generation, and minimize the accumulation of inhibitory metabolites such as lactate and ammonia. Improved nutrient efficiency often translates into higher product yields per unit of media and feed consumed, ultimately reducing the cost of producing each gram of biologic product.
In addition, maintaining cultures in a more balanced metabolic state can improve cell viability, extend productive culture duration, and enhance consistency of critical quality attributes. As a result, spent media analysis and media fortification support a dual objective: maximizing process productivity while simultaneously lowering manufacturing costs and maintaining GMP quality requirements.
Because media composition, feeding strategy, temperature, dissolved oxygen, and pH are highly interconnected, biologics development increasingly relies on Design of Experiments (DoE) rather than sequential one-factor-at-a-time studies.
DoE enables scientists to understand how multiple process variables interact and how those interactions affect both productivity and CQAs. Instead of identifying a single optimum condition, it establishes a scientifically justified design space within which process performance and product quality remain consistent.
This knowledge forms the foundation of Quality by Design (QbD), allowing manufacturers to demonstrate process understanding, establish critical process parameters (CPPs), and develop robust control strategies that support GMP manufacturing.
Consequently, DoE contributes not only to faster development but also to greater regulatory confidence and smoother technology transfer.
Process intensification has emerged as one of the most effective approaches for reducing COGS because it increases the amount of product generated from existing manufacturing assets.
Increasingly, manufacturers are also adopting N-stage intensification strategies, including retention-based processes utilizing ATF or TFF technologies. These systems employ membranes with appropriate molecular weight cut-offs to retain cells and, where desired, product within the bioreactor while continuously removing waste metabolites and replenishing fresh nutrients. By maintaining a more favourable culture environment, these approaches support higher cell densities, prolonged culture productivity, and increased volumetric yields.
When combined with spent media analysis and targeted media fortification, intensified processes can further improve nutrient utilization efficiency by supplying only the nutrients required to sustain optimal cellular performance. This reduces the consumption of underutilized media and feed components while increasing product yield per unit of raw material consumed. The combined effect of higher productivity, lower media and feed usage, improved facility utilization, and reduced manufacturing cost per gram contributes to meaningful COGS reduction
At Aragen, these considerations are incorporated into the CHOMax™ platform, where cell line development, media optimization, spent media analysis, media fortification, and process intensification are evaluated as an integrated workflow. Both N-1 and N-stage intensification strategies are assessed not only for productivity gains but also for their impact on product quality, process robustness, scalability, and manufacturability. This integrated approach helps translate productivity improvements into measurable COGS reductions while maintaining GMP-quality product attributes.
As processes become more complex, maintaining consistent quality requires greater process visibility.
Process Analytical Technologies (PAT) enable real-time monitoring of key process indicators such as nutrient consumption and metabolic activity. Rather than relying on fixed feeding schedules, PAT-supported processes can adjust feeding based on the actual condition of the culture.
This shift from schedule-based operation to data-driven control helps maintain metabolic consistency, reduces variability, and strengthens control of CPPs that influence CQAs.
From a GMP perspective, PAT also supports a more proactive manufacturing strategy by enabling earlier detection of process deviations and strengthening overall process robustness.
A process that performs well at laboratory scale has limited value if product quality changes during scale-up.
Successful scale-up depends on maintaining relationships between CPPs and CQAs across different manufacturing scales. Parameters such as media composition, feeding strategy, pH, dissolved oxygen, temperature, and osmolality must remain scientifically linked to product quality throughout development and GMP production.
When these relationships are understood and controlled, manufacturers can transfer processes into commercial-scale operations with greater confidence, reducing both technical risk and development timelines.
Reducing COGS while maintaining GMP quality is not a trade-off. It is the outcome of a well-designed, data-driven process development strategy.
Advanced media optimization, metabolically balanced feeding strategies, spent media analysis, targeted media fortification, process intensification, and PAT-enabled monitoring help manufacturers improve productivity while maintaining control of critical quality attributes. By understanding nutrient utilization and cellular metabolism, organizations can reduce unnecessary media and feed consumption, improve raw material efficiency, and generate more product from existing manufacturing assets.
Similarly, intensification strategies such as N-1 expansion and retention-based N-stage processes enable higher volumetric productivity while maintaining a favorable cellular environment through continuous nutrient replenishment and waste metabolite removal. When combined with data-driven media and feed optimization, these approaches can significantly improve facility utilization and reduce manufacturing cost per gram of product.
Ultimately, successful biologics manufacturing depends on integrating productivity, quality, and cost considerations from the earliest stages of process development. Organizations that build process understanding and quality into development are better positioned to scale efficiently, meet regulatory expectations, and accelerate commercialization while achieving sustainable COGS reduction.
Ready to reduce COGS while maintaining product quality? Connect with Aragen Bioscience’s CHOMax™ experts to explore integrated cell line, media, and process development solutions tailored to your biologics program.
Contributed and reviewed by
Prithwish Dey
General Manager MSAT & Process Development
Aragen Biologics, Bengaluru, India
